The μ-opioid receptor is the principal site of action in the brain by which morphine, other
opiate drugs of abuse, and endogenous opioid peptides effect analgesia and alter mood. A …

A general method of confocal laser scanning microscopy was used to demonstrate specific
binding of fluorescein-labeled naloxone (FNAL, 10–50 nM) to stably transfected mu opioid …

The effects of acute and chronic administration of (MK-801; [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine
hydrogen maleate) were assessed on morphine …

Cells grown in monolayer culture offer a convenient system for binding and other experiments
under conditions that preserve the complexity of the living state. Kinetics experiments, …

We have previously shown that ascorbic acid (AA) protects cortical neurons in culture from
the toxic effects of NMDA. In the present study, we examined the interactions of AA with …

This study investigated the role of (MK-801; [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]-cyclo-hepten-5,10-imine
hydrogen maleate) in the development and expression of tolerance to …

The antagonist β‐funaltrexamine (β‐FNA), known to bind covalently to μ‐opioid receptors
by a two‐step, doubly discriminating sequence, was used as a sensitive gauge to compare …

To investigate a previous observation that classical antagonists behave as agonists at mutant
H297N and H297Q μ opioid receptors, we compared the kinetics of recovery from opioids …

The two‐stage reaction whereby the antagonist β‐funaltrexamine (β‐FNA) binds covalently
to μ opioid receptors makes it a highly discriminating probe into the tertiary structure of the …

This chapter addresses a number of issues pertaining to the supervision of female offenders
and ‘compliance’, looking in particular at evidence on gendered aspects of work with …